

Application No.: 09/055,818

Docket No.: BAKER 3.0-002 CIP CIP CIP I

IN THE SPECIFICATION

Amend the paragraph beginning at page 4, line 4 as follows:

Docetaxel (N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl paclitaxel) has become commercially available as TAXOTERE® (Rhone-Poulenc-Rorer S.A.) in parenteral form for the treatment of breast cancer. To date, no reference has been made in the scientific literature to oral absorption of docetaxel in animals or patients.

Amend the paragraph beginning at page 10, line 18 as follows:

Preferred viscosity-reducing co-solubilizers include, e.g., PHARMASOLVE™ (N-methyl-2-pyrrolidone, International Specialty Products, Wayne, NJ); MIGLYOL™ glycerol or propylene glycol esters of caprylic and capric acids (Hüls AG, Marl, Germany); polyoxyethylated hydroxystearates (e.g., SOLUTOL™ HS 15); TWEEN™ polyoxyethylated sorbitan esters; SOFTIGEN™ polyethylene glycol esters of caprylic and capric acids (Hüls AG); modified castor oils (such as CREMOPHOR™ EL or RH 40); vegetable oils such as olive oil, polyoxyethylated fatty ethers or modified castor oils; certain saturated polyglycolized glycerides (such as a LABRASOL™) citrate esters such as tributyl citrate, triethyl citrate and acetyl triethyl citrate; propylene glycol, alone or in combination with PHARMASOLVE™; ethanol; water; and lower molecular weight polyethylene glycols such as PEG 200 and 400.

Amend the paragraph beginning at page 15, line 1 as follows:

Cyclosporins are a group of nonpolar cyclic oligopeptides (some of which have immunosuppressant activity) produced by the genus Topycladium, Tolypocladium, including, e.g., Topycladium inflatum Gams Tolypocladium inflatum Gams (formerly designated as Trichoderma Polysporum), Topycladium

Application No.: 09/055,818

Docket No.: BAKER 3.0-002 CIP CIP CIP I

D³

~~terricola~~ Tolypocladium terricola and other fungi imperfecti. The major component, cyclosporin A (cyclosporine or CsA), has been identified along with several other lesser metabolites, for example, cyclosporins B through Z, some of which exhibit substantially less immunosuppressive activity than cyclosporin A. A number of synthetic and semi-synthetic analogs have also been prepared. See generally Jergorov et al., Phytochemistry, 38: 403-407 (1995). The present invention comprehends natural, semi-synthetic and synthetic analogs of cyclosporins.

Amend the asterisk footnotes at the bottom of Example 3 and 4 on page 25 as follows:

D⁴

* Not an actual HLB value of mixture. Numbers represent HLB values of pure Surfactants.

Amend the paragraph beginning at page 27, line 3 as follows:

D⁵

Table 8 pertains to vehicle formulations containing saturated ~~polyglycolized~~ polyglycolyzed glycerides as carriers. The data set forth correspond to the data described in Example 2 with respect to Table 3.